Apr. 27, 2011 (GlobeNewswire) -- VANCOUVER, British Columbia, April 27, 2011 (GLOBE NEWSWIRE) -- Global Health Ventures Inc. (OTCBB:GHLV), a specialty pharmaceutical company, is pleased to announce that it has started discussions for the clinical trials of X-Excite in North America. The Company has endorsed the work with Omnicare of Philadelphia on the detail of the clinical trials and statistical power required.
The Company has obtained valuable information on the European clinical trials for X-Excite and will begin designing a successful trial in the United States. The work will be conducted by Omnicare, a well-respected and internationally known contract research organization (CRO). Omnicare is a U.S. based CRO with its head office in Philadelphia, PA including twenty other offices throughout the world.
|
|
Read more...
|
|
|
Apr. 26, 2011 (Marketwire) --LAS VEGAS, NV -- (Marketwire) -- 04/26/11 -- Oriens Travel & Hotel Management Corp. (PINKSHEETS: OTHM) www.OriensCorp.com, the Next Generation Global Boutique Hotel Brand Operator, operating its Hotel PURE brand (www.HotelPURE.com), is pleased to announce the company has retained Premier Media Services Inc. as its investor relations firm. Arizona-based Premier Media Services Inc. is a full service investor and media relations consulting firm, provides both private and publicly traded companies customized programs to generate awareness among members of the financial community. Premier Media specializes in accelerating growth in the value of small to mid-size companies.
|
|
Read more...
|
|
Apr. 21, 2011 (Marketwire) -- LAS VEGAS, NV -- (Marketwire) -- 04/21/11 -- Willow Creek Enterprises, Inc. (OTCBB: WLOC) (the "Company" or "Willow Creek") is pleased to announce that it has completed the acquisition of two new mineral claims that was previously announced on April 7, 2011. The two new mineral claims total 40 acres and are surrounded by the Company's Hercules Property in Lyon County, Nevada. The claims will increase the existing Hercules Property to 88 mining claims and 1760 acres.
Terry Fields, President, Willow Creek, stated, "This is a very strategic acquisition for us. We believe that the new claims will have an immediate and positive effect on the development of our Hercules Project. Based on our initial assessment of the property, we will be looking at the possibility of immediately increasing the inferred resource at Hercules. We believe this is definitely an exciting time for Willow Creek investors, management and employees."
|
|
Read more...
|
|
Apr. 19, 2011 (Marketwire) -- ORLANDO, FL -- (Marketwire) -- 04/19/11 -- GDT Tek, Inc. (PINKSHEETS: GDTK) today announced that GDT Tek's appearance at "GreenStock-Concert Series and Expo" was met with enthusiasm and interest from its attendees.
The President of GDT Tek, Bo Linton, was available to answer questions about the Company and met with attendees and answered questions about GDT Tek during the expo.
|
|
Read more...
|
April 19, 2011 - - White House Blog - As the President answered questions at a town hall at Northern Virginia Community College, it was clear that the concerns people have outside Washington are directly related to the debate over our budget and fiscal future that will be playing out over the coming months. People were rightly concerned about getting our deficits under control, but they were also concerned about our future in education, clean energy, and Medicare. Read the full transcript to see his detailed answers, but his summary of his plan and the choices ahead of us in his opening remarks made clear that we can address both issues:
|
|
Read more...
|
|
VANCOUVER, British Columbia, April 12, 2011 (GLOBE NEWSWIRE) -- Global Health Ventures Inc. (OTCBB:GHLV) a specialty pharmaceutical company is pleased to announce that has completed the final formulation of its lead therapeutics drug, X-Excite for the upcoming clinical trials in the United States. Results of the interim clinical trials in Europe showed X-Excite to appear in the blood rapidly and stay for longer time than the brand, Viagra®. It is believed the longer presence of the drug in the blood may contribute to both buccal (sublingual) absorption and the gastric absorption. For North American trials, the Company has modified the formulation slightly to give the maximal buccal absorption.
"We are very pleased with the results of our European clinical trials. Now we have fine tuned our formulation for the North American clinical trials. With the final formulation, we can now contract out the GMP manufacturing of the drug to a qualified Contract Manufacturing Organization (CMO) and initiate the clinical trials soon after having the drug on hand," said Dr. Hassan Salari, President & CEO of Global Health.
|
|
Read more...
|
|
|
|
|
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>
|
|
Page 12 of 42 |
.gif)
